ERBB2 and breast carcinoma: This biological nature of HER2 subtype further motivated the discovery of ImmunoSkew, a quantitative measure of intra-tumour heterogeneity of lymphocytic infiltrate that can potentially serve as a prognostic biomarker in HER2 breast cancer based on routinely generated histology samples.